Clinical Trial

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Study acronym: HIPANIV
Unknown Phase 1
View on ClinicalTrials.gov →
Summary
To determine the Maximum Tolerated Dose (MTD), and the recommended Phase 2 dose of HIA Ipilimumab in combination with IV Nivolumab by monitoring the Dose Limiting Toxicity (DLT) within 1 month after IA Ipilimumab administration in dose-escalation phase.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04823403
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Hepatocellular Carcinoma
Enrollment 27 participants
Start Date 2020-11-13
Primary Completion 2022-11-04 (estimated)
Study Completion 2024-11 (estimated)
Updated on ClinicalTrials.gov 2024-07-26